Avadel Pharmaceuticals Plc (AVDL)
21.64
0.00 (0.00%)
USD |
NASDAQ |
Nov 13, 16:00
Avadel Pharmaceuticals Enterprise Value
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 2.050B |
| November 12, 2026 | 2.050B |
| November 11, 2026 | 2.050B |
| November 10, 2026 | 2.050B |
| November 09, 2026 | 2.050B |
| November 06, 2026 | 2.050B |
| November 05, 2026 | 2.050B |
| November 04, 2026 | 2.050B |
| November 03, 2026 | 2.050B |
| November 02, 2026 | 2.050B |
| October 30, 2026 | 2.050B |
| October 29, 2026 | 2.050B |
| October 28, 2026 | 2.050B |
| October 27, 2026 | 2.050B |
| October 26, 2026 | 2.050B |
| October 23, 2026 | 2.050B |
| October 22, 2026 | 2.050B |
| October 21, 2026 | 2.050B |
| October 20, 2026 | 2.050B |
| October 19, 2026 | 2.050B |
| October 16, 2026 | 2.050B |
| October 15, 2026 | 2.050B |
| October 14, 2026 | 2.050B |
| October 13, 2026 | 2.050B |
| October 12, 2026 | 2.050B |
| Date | Value |
|---|---|
| October 09, 2026 | 2.050B |
| October 08, 2026 | 2.050B |
| October 07, 2026 | 2.050B |
| October 06, 2026 | 2.050B |
| October 05, 2026 | 2.050B |
| October 02, 2026 | 2.050B |
| October 01, 2026 | 2.050B |
| September 30, 2026 | 2.050B |
| September 29, 2026 | 2.050B |
| September 28, 2026 | 2.050B |
| September 25, 2026 | 2.050B |
| September 24, 2026 | 2.050B |
| September 23, 2026 | 2.050B |
| September 22, 2026 | 2.050B |
| September 21, 2026 | 2.050B |
| September 18, 2026 | 2.050B |
| September 17, 2026 | 2.050B |
| September 16, 2026 | 2.050B |
| September 15, 2026 | 2.050B |
| September 14, 2026 | 2.050B |
| September 11, 2026 | 2.050B |
| September 10, 2026 | 2.050B |
| September 09, 2026 | 2.050B |
| September 08, 2026 | 2.050B |
| September 04, 2026 | 2.050B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Jazz Pharmaceuticals Plc | 18.27B |
| GH Research Plc | 948.78M |
| Cosmo NV | -- |
| Alkermes Plc | 8.718B |
| Amarin Corp. Plc | -78.32M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 0.02M |
| Revenue (Quarterly) | 77.47M |
| Total Expenses (Quarterly) | 77.45M |
| EPS Diluted (Quarterly) | 0.0002 |